Spencer D. Brown Net Worth

What's Spencer Brown's mailing address?

Spencer's mailing address filed with the SEC is C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, SUITE 300, FLORHAM PARK, NJ, 07932.

Insiders trading at PDS Biotechnology

Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin и Kamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.

What does PDS Biotechnology do?

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati

PDS Biotechnology executives and stock owners

PDS Biotechnology executives and other stock owners filed with the SEC include:

• Frank Bedu-Addo,
  President, Chief Executive Officer, Director
• Dr. Frank K. Bedu-Addo Ph.D.,
  Pres, CEO & Director
• Gregory Conn,
  Chief Scientific Officer
• Lauren V. Wood M.D.,
  Chief Medical Officer
• Dr. Gregory L. Conn,
  Chief Scientific Officer
• Gregory Freitag,
  Independent Director
• DeLyle Bloomquist,
  Independent Director
• Stephen Glover,
  Independent Chairman of the Board
• Richard Sykes,
  Independent Director
• Otis Brawley,
  Director
• Deanne Randolph,
  Investor Relations
• Kamil Ali-Jackson,
  Independent Director
• Ilian Iliev,
  Director
• Lauren Wood,
  Chief Medical Officer
• Michael King,
  Interim Chief Financial Officer
• Janetta Trochimiuk,
  Controller
• Dr. Mark Baxter Ph.D.,
  Sr. VP of Global Quality
• Hillary Yegen,
  VP of Legal
• Dr. Joe J. Dervan,
  VP of R&D
• Matthew C. Hill CPA,
  CFO & Principal Accounting Officer
• Matthew C Hill,
  Chief Financial Officer
• James J Loughlin,
  Director
• Voorhees Seth Van,
  Chief Financial Officer
• Lars Boesgaard,
  Chief Financial Officer
• Spencer D. Brown,
  Senior VP, General Counsel
• Kirk V. Shepard,
  Chief Medical Officer
• Stephan Toutain,
  Chief Operations Officer